UPDATE: J.P. Morgan Downgrades United Therapeutics to Neutral

J.P. Morgan is out with its report today on United Therapeutics UTHR, downgrading UTHR to Neutral from Overweight. In its report, J.P. Morgan writes, "In the meantime, we wouldn't expect the Street to be comfortable with upside drivers beyond oral, and, as such, we're downgrading UTHR shares to Neutral from Overweight." J.P. Morgan lowers PT on UTHR to $55 from $75. At the time of posting, shares of UTHR were trading pre-market at $39.12, down 19.77% from Tuesday's close.